Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company focused on therapies for people impacted by kidney disease, and its news flow reflects this specialization. Company announcements frequently highlight progress with Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. Updates include prescribing access among dialysis organizations, clinical trial data such as post-hoc analyses from the INNO2VATE trials, and real-world studies like VOICE and VOCAL that examine mortality, hospitalization, and dosing strategies.
News releases also cover Akebia’s rare kidney disease pipeline, including praliciguat and AKB-097. Investors can follow milestones such as the first patient dosed in a Phase 2 trial of praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS), plans to evaluate praliciguat in other rare podocytopathies, and the planned Phase 2 basket study of AKB-097 across complement-mediated rare kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional pipeline updates may involve AKB-9090, a HIF-PH inhibitor entering Phase 1 for acute kidney injury associated with cardiac surgery.
Akebia’s news stream also includes financial results, stock option inducement grants under Nasdaq Listing Rule 5635(c)(4), licensing and supply agreements such as amendments to its Vafseo license with Medice in Europe and certain other countries, and participation in healthcare and investor conferences. For investors tracking AKBA, this news page provides a centralized view of clinical, regulatory, commercial, and corporate developments that shape the company’s kidney disease franchise and pipeline trajectory.
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to eight newly-hired employees. The inducement grants total 148,000 shares of common stock with an exercise price of $2.41 per share, matching the closing price on April 30, 2025. The options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia.
Akebia Therapeutics (NASDAQ: AKBA) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, before market open. The company will host a conference call at 8:00 a.m. EDT on the same day to discuss the financial results and recent business highlights.
Participants are encouraged to dial in 15 minutes before the scheduled start time to ensure timely connection. A live webcast will be available through Akebia's Investors section website, with an online archive accessible afterward at ir.akebia.com.
Akebia Therapeutics (AKBA) announced that the European Medicines Agency's CHMP has adopted a positive opinion recommending approval for XOANACYL® (Ferric Citrate as Coordination Complex). The drug is intended for treating elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
The treatment rights in the European Economic Area and certain countries in Europe and the Middle East are licensed to Averoa, a renal-focused biopharmaceutical company. The European Commission is expected to make a final decision on XOANACYL's approval in approximately two months.
Akebia Therapeutics (Nasdaq: AKBA) has announced the granting of stock options to eight newly-hired employees as part of their inducement award program. The grants, made on March 31, 2025, total 73,325 shares of common stock with an exercise price of $1.92 per share, matching the closing price on the grant date.
The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) announced its upcoming participation at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston from April 10-13, 2025. The company will present two research posters:
1. A study on cardiovascular risk in patients with DD-CKD comparing Vadadustat vs Darbepoetin Alfa (Poster: G-284)
2. Research on Vadadustat's treatment of anemia comparing older vs younger patients with Dialysis-Dependent-CKD (Poster: G-285)
Dr. Wolfgang Winkelmayer will present the latter study during an oral presentation on April 10, 2025, at 4:00 pm. Attendees can visit Akebia at Booth #1121 in the Exhibit Hall.
Akebia Therapeutics (Nasdaq: AKBA) has announced the pricing of its underwritten public offering of 25,000,000 shares of common stock at $2.00 per share. The offering is expected to generate gross proceeds of $50.0 million before deducting underwriting costs and other expenses.
The company has granted underwriters a 30-day option to purchase up to 3,750,000 additional shares at the public offering price, less underwriting discounts. The offering is set to close on March 21, 2025, subject to customary conditions.
The offering is being managed by Leerink Partners and Piper Sandler & Co. as joint bookrunning managers, with BTIG, as lead manager and H.C. Wainwright & Co. as co-manager. The shares are being offered through a shelf registration statement filed with the SEC on September 3, 2024.
Akebia Therapeutics (Nasdaq: AKBA) has announced the commencement of an underwritten public offering of common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price, less underwriting discounts and commissions.
The offering will be managed jointly by Leerink Partners and Piper Sandler & Co. as bookrunning managers. The shares are being offered through a shelf registration statement filed with the SEC on September 3, 2024, and declared effective on September 12, 2024.
The offering's final terms will be disclosed in a final prospectus supplement to be filed with the SEC. The completion, size, and terms of the offering are subject to market conditions.
Akebia Therapeutics (AKBA) reported its Q4 and full-year 2024 financial results, highlighting the successful launch of Vafseo® (vadadustat) in January 2025. The company expects Q1 2025 Vafseo net product revenues of $10-$11 million.
Key financial metrics for Q4 2024 include:
- Total revenues: $46.5M (down from $56.2M in Q4 2023)
- Auryxia® net product revenues: $44.4M (down from $53.2M)
- Net loss: $22.8M (compared to $0.6M net income in Q4 2023)
- Cash position: $51.9M as of December 31, 2024
The company secured commercial supply contracts with dialysis organizations covering nearly 100% of U.S. dialysis patients. Over 500 prescribers have written prescriptions for Vafseo, averaging 8 prescriptions each. Akebia plans to initiate the Phase 3 VALOR trial for non-dialysis CKD patients in H2 2025 and expects current cash resources to fund operations for at least two years.
Akebia Therapeutics (Nasdaq: AKBA) has scheduled the release of its fourth quarter and full year 2024 financial results on Thursday, March 13, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day to discuss the financial performance and recent business developments.
Investors and interested parties can access the conference call through a registration link, with recommended dial-in 15 minutes before the scheduled start time. A live webcast will be available through the Investors section of Akebia's website, with an online archive accessible afterward at ir.akebia.com.
FAQ
What is the current stock price of Akebia Therapeut (AKBA)?
What is the market cap of Akebia Therapeut (AKBA)?
